Understanding the Benzo Class: A Comprehensive Guide for Automotive Technicians and Healthcare Professionals

Benzodiazepines, commonly referred to as the “Benzo Class,” are a group of medications acting on benzodiazepine receptors within the central nervous system. While seemingly disparate from the automotive repair field, understanding the effects and implications of this drug class is crucial for professionals in various sectors, including website content creators for platforms like mercedesxentry.store, especially if the audience includes individuals in healthcare or related fields. These medications, including FDA-approved options like alprazolam, clobazam, and chlordiazepoxide, play a vital role in managing various medical conditions, most notably seizure activity, accounting for a significant percentage of emergency department visits in the United States. Beyond seizure control, the benzo class is utilized for insomnia, acute status epilepticus, amnesia induction, agitation, anxiety, and spastic disorders.

For automotive technicians and content creators in the automotive niche, understanding the benzo class can indirectly enhance safety awareness, particularly concerning customers or colleagues who might be taking these medications. Furthermore, as content creators for mercedesxentry.store, knowledge of diverse topics, including health-related information that might intersect with customer well-being, demonstrates a broader understanding and expertise.

This article provides a comprehensive overview of the benzo class, detailing their indications, mechanism of action, safe administration, adverse effects, contraindications, toxicology, and essential monitoring practices within a clinical setting. It emphasizes the importance of a thorough understanding of these medications for healthcare professionals and indirectly for related fields, promoting informed decision-making, patient safety, and comprehensive care. The collaborative role of an interprofessional healthcare team in ensuring focused, secure, and personalized care when utilizing the benzo class is also highlighted.

Objectives:

Differentiate the various medications within the benzo class, recognizing their distinct pharmacological profiles, dosages, and potential side effects.
Develop personalized treatment strategies, optimizing dosages of the benzo class based on individual patient requirements and responses.
Determine appropriate monitoring methods for the safe and effective use of the benzo class, including routine evaluations of therapeutic outcomes and possible adverse reactions.
Foster collaboration within an interprofessional healthcare team to exchange knowledge, discuss patient cases, and ensure a holistic approach to managing patients on the benzo class.

Access free multiple choice questions on this topic.

Indications for the Benzo Class

Medications belonging to the benzo class exert their therapeutic effects by interacting with benzodiazepine receptors in the central nervous system (CNS). Their effectiveness in ceasing seizure activity is well-established, evidenced by their involvement in a notable fraction of annual emergency department visits across the United States. The clinical applications of the benzo class are diverse, addressing conditions such as insomnia, acute status epilepticus, inducing amnesia, managing agitation and anxiety, and alleviating spastic and seizure disorders. Psychiatry frequently utilizes the benzo class for off-label purposes, extending to conditions like Tourette syndrome, delirium, delirium tremens, various sleep disorders, and medication-induced movement abnormalities including tremors, tics, tardive dyskinesia, and chorea.[1][2]

FDA-Approved Uses of the Benzo Class

The United States Food and Drug Administration (FDA) has granted approval for specific medications within the benzo class for managing anxiety, seizures, and alcohol withdrawal, as detailed below:

Chlordiazepoxide: This benzo class member is primarily indicated for managing alcohol withdrawal syndrome.[4]
Clonazepam: Clonazepam, part of the benzo class, is approved for treating panic disorder and agoraphobia.[3] It is also indicated for managing myoclonic and absence seizures.[6]
Diazepam: Diazepam, within the benzo class, is utilized for alcohol withdrawal management.[7] Rectal diazepam is also indicated for managing febrile seizures.[8]
Flurazepam: Flurazepam, a benzo class medication, is indicated for insomnia treatment.[9]
Midazolam: Midazolam, belonging to the benzo class, is indicated for convulsive status epilepticus and procedural sedation. It is also used for sedation in mechanically ventilated patients in intensive care settings.[11]
Quazepam: Quazepam, a benzo class medication, is primarily indicated for chronic insomnia in adults, according to the American College of Physicians.[13]
Triazolam: Triazolam, within the benzo class, is primarily indicated for sleep-onset insomnia.
Remimazolam: Remimazolam, a newer addition to the benzo class approved by the FDA in 2020, is indicated for short-duration procedures. [14]

Alt text: Depiction of a benzodiazepine molecule’s chemical structure, highlighting its core components.

Mechanism of Action of the Benzo Class

The benzo class of drugs exerts its effects by interacting with benzodiazepine receptors in the CNS. These receptors are protein complexes composed of five transmembrane subunits forming a chloride channel, specifically the gamma-aminobutyric acid type A (GABA-A) receptor. These subunits consist of two alpha, two beta, and one gamma subunit. GABA, an inhibitory neurotransmitter, binds to a receptor site formed by the extracellular portions of the alpha and beta subunits. Benzodiazepines, within the benzo class, bind to a site formed by the extracellular portions of the alpha and gamma subunits.

Activation of benzodiazepine receptors by the benzo class induces a conformational change in the central pore, facilitating the entry of chloride ions into the neuron. This influx of chloride anions leads to neuronal hyperpolarization, resulting in CNS depression.[15] The benzo class enhances the frequency of GABA-A receptor chloride channel opening in the presence of GABA. Importantly, in the absence of GABA, benzodiazepines have no effect on GABA-A receptor function.[16] This mechanism of action is central to understanding how the benzo class achieves its therapeutic effects.

Pharmacokinetics of the Benzo Class

Understanding the pharmacokinetics of the benzo class is crucial for effective clinical application.

Absorption: Following oral administration, the benzo class is generally well-absorbed from the gastrointestinal tract, with the exception of clorazepate, which undergoes decarboxylation in gastric juice before absorption. Intramuscular (IM) injection results in slow absorption for diazepam and chlordiazepoxide, while lorazepam and midazolam are absorbed more rapidly via this route. Intravenous (IV) administration of the benzo class leads to rapid distribution to the brain and CNS. Midazolam, known for its lipophilic nature within the benzo class, readily crosses the blood-brain barrier, leading to a swift onset of clinical effects.

Distribution: Benzodiazepines and their active metabolites exhibit high plasma protein binding. For instance, plasma protein binding is approximately 70% for alprazolam, 85% for clonazepam, and 99% for diazepam. The concentration of the benzo class in cerebrospinal fluid is roughly equivalent to the free drug concentration in plasma. Diazepam, in particular, undergoes rapid redistribution.

Metabolism: Metabolism of the benzo class typically occurs in three phases. The first phase involves N-desalkylation, producing biologically active metabolites, except for triazolam, alprazolam, and midazolam. The second phase involves hydroxylation, usually yielding an active derivative. The final phase is conjugation with glucuronic acid. Hepatic CYP3A4 and CYP2C19 enzymes extensively metabolize most members of the benzo class. Lorazepam, however, undergoes direct glucuronidation without cytochrome P450 metabolism, making it aConsideration for patients with hepatic dysfunction.[17] Remimazolam is metabolized to a metabolite (CNS7054) with negligible hypnotic activity.[18]

Elimination: The kidneys primarily excrete benzodiazepines and their metabolites. Diazepam produces active metabolites like oxazepam, temazepam, and desmethyldiazepam, extending the drug’s duration of action. The elimination half-life of the benzo class can be prolonged in older patients and those with renal dysfunction.[19]

Alt text: Diagram illustrating the mechanism of action of benzodiazepines on the GABA-A receptor, showing enhanced chloride ion flow.

Administration of the Benzo Class

Available Dosage Forms and Strengths

The benzo class is commonly administered orally and intravenously. Rectal, intranasal, and intramuscular routes are also utilized as dictated by clinical protocols. Intranasal or IM administration may be particularly useful in actively seizing patients when IV or oral routes are not feasible. Rectal administration in pediatric patients can be used for seizure cessation when IV access is not established.

Administering the benzo class involves incremental dosing until desired effects like sedation, seizure cessation, and anxiolysis are achieved. However, achieving therapeutic CNS drug concentrations via IV administration can take 3 to 5 minutes. Therefore, sufficient time should be allowed between doses to prevent over-sedation.

Crucially, clinicians must ensure the availability of resuscitation and airway management equipment during benzo class administration. This equipment may include nasopharyngeal or oropharyngeal airways, bag valve masks, blind insertion airway devices, laryngeal mask airways, or endotracheal intubation, depending on the training of emergency medical service providers. Diazepam milligram equivalency can be used to estimate conversion factors between different members of the benzo class.[20]

Adult Dosage Guidelines for Benzo Class Members

Alprazolam: For generalized anxiety disorder, initiate treatment with 0.25 to 0.5 mg three times daily. The dose can be increased every 3 to 4 days up to a maximum daily dose of 4 mg. For panic disorders, 1 to 4 mg/day is typically used. Due to dependence potential, use the minimal effective clinical dose.[3]
Chlordiazepoxide: For alcohol withdrawal syndrome, the initial dose is 50 to 100 mg, followed by up to 300 mg/day as needed, adjusted according to the CIWA-Ar protocol.[21]
Clonazepam: For panic disorder, the initial adult dose is 0.5 mg/day, with a maintenance dose of 1 mg/day for most patients. For seizure disorders, 0.5 mg three times daily is given, with a maximum recommended daily dose of 20 mg.
Clobazam: For Lennox-Gastaut syndrome as an adjunct to antiepileptic drugs, the initial dose is 10 mg for patients over 30 kg, increased to 20 mg after one week, with a usual maintenance dose of 40 mg after two weeks. In patients under 30 kg, dosing adjustments are necessary. [5]
Clorazepate: For focal (partial) onset seizures in patients over 12 years, the initial dose is 7.5 mg three times daily, with a maximum recommended dose of 90 mg/day.[7]
Diazepam: ASAM 2020 guidelines recommend front-loading for severe alcohol withdrawal (CIWA-Ar ≥19) using symptom-triggered (e.g., 10 mg diazepam orally hourly if CIWA-Ar ≥10) or fixed-schedule regimens (e.g., 20 mg diazepam orally every 2 hours for 3 doses).[12] Rectal diazepam for febrile seizures is dosed at 0.5 mg/kg.[8][22]
Estazolam: For sleep onset and maintenance insomnia, estazolam is dosed at 1 to 2 mg at bedtime, according to AASM guidelines.[9]
Flurazepam: For insomnia, the recommended dose is 15 mg for women and 30 mg for men.
Lorazepam: For convulsive status epilepticus, IV lorazepam (0.1 mg/kg, maximum 4 mg) is the initial dose, which may be repeated at 3 to 5-minute intervals per AES guidelines.[10]
Midazolam: For convulsive status epilepticus, 10 mg IM midazolam is administered as a single dose, preferred for patients without IV access. Intranasal midazolam (0.2 mg/kg, maximum 10 mg) can be used pre-hospitally. For procedural sedation, dosing varies.[11][23][[24]](#article-18220.r24]
Oxazepam: For alcohol withdrawal syndrome, symptom-triggered dosing is used. For CIWA-Ar scores of 8 to 15, 15 mg oxazepam is given; for scores >15, 30 mg oxazepam is administered.[12]
Quazepam: As an alternative for sleep onset and maintenance insomnia, the recommended dose is 7.5 mg/day at bedtime, potentially increased to 15 mg, but with caution due to long half-life and potential for accumulation and daytime impairment.[13]
Temazepam: For sleep onset and maintenance insomnia, the recommended dose is 7.5 to 15 mg daily at bedtime, improving total sleep time, sleep latency, and sleep quality. Cognitive behavioral therapy is recommended as initial treatment for chronic insomnia.[9][13]
Triazolam: Primarily for sleep-onset insomnia, the recommended dose is 0.125 to 0.25 mg daily at bedtime, limited to 4 to 8 weeks of use.[12]
Remimazolam: Approved in 2020, remimazolam is indicated for short-duration procedures. [14]

Specific Patient Populations and Benzo Class Use

Hepatic impairment: Lorazepam and oxazepam metabolism is minimally affected by liver disease, making lorazepam a safer empiric choice for alcohol withdrawal and hepatic impairment. Remimazolam should be used cautiously in severe hepatic impairment.[25]
Renal impairment: Reduced clearance and plasma protein binding in renal impairment increase unbound benzodiazepine concentrations. Lorazepam may be safer in ESRD, while diazepam carries accumulation risks. Lower starting doses and cautious titration are recommended for the benzo class in renal impairment.[19][26]
Pregnancy considerations: Most benzodiazepines were formerly FDA pregnancy category D, indicating fetal risk, but potential benefits may justify use in pregnant women (especially during maternal seizures). Diazepam and chlordiazepoxide have been linked to congenital malformations, including cleft palate. Flurazepam and temazepam are pregnancy class X due to neonatal lethargy and skeletal development issues. The benzo class should be largely avoided in the first trimester.[27] NICE guidelines advise against benzodiazepines in pregnancy, but they can be used for severe anxiety, agitation, and seizures. Benzodiazepine use in pregnancy is associated with neonatal hypotonia and withdrawal. Pre-pregnancy counseling to taper benzodiazepines is important.[28][29]
Breastfeeding considerations: Caution is needed in neonates and preterm infants due to hypotension risks, especially with opioids like fentanyl. Midazolam, lorazepam, and oxazepam are suggested as cautiously usable based on safety scoring systems. Benzodiazepides during lactation should be avoided unless strongly indicated.[30][31][32]
Older patients: The AGS Beers Criteria identifies benzodiazepines as potentially inappropriate for older adults due to increased sensitivity and reduced clearance, leading to risks of cognitive impairment, falls, and fractures. However, reasonable use may be warranted for seizure disorders, alcohol withdrawal, periprocedural sedation, and severe generalized anxiety disorder.[33]
Pediatric patients: For seizures lasting over 5 minutes, IV lorazepam and diazepam are effective per AES guidelines. Rectal diazepam, IM midazolam, intranasal midazolam, and buccal midazolam are also likely effective.[10]

Alt text: Assortment of benzodiazepine pills in various shapes, sizes, and colors, representing different medications within the class.

Adverse Effects of the Benzo Class

Administration of the benzo class can lead to several common adverse effects, including respiratory depression, respiratory arrest, drowsiness, confusion, headache, syncope, nausea, vomiting, diarrhea, and tremors.

In neonates, laryngospasm and bronchospasm occur in less than 1% of patients treated with benzodiazepines. Ventricular arrhythmias, including ventricular bigeminy or premature ventricular contractions, vasovagal syncope, bradycardia, or tachycardia may also occur. Gastrointestinal reactions can include retching, nausea, vomiting, and excessive salivation. CNS and neuromuscular adverse effects may include euphoria, hallucinations, ataxia, dizziness, seizure-like activity, and paresthesia.

Visual disturbances such as diplopia (“double vision”), cyclic eyelid movement, loss of balance, and difficulty focusing can occur. Long-term use of the benzo class can result in cognitive impairment.[34] Rare cases of cholestatic liver injury have been reported with benzodiazepines like alprazolam, clonazepam, diazepam, and flurazepam.[35] Remimazolam can cause both hypertension and hypotension, requiring blood pressure monitoring during procedures.[36]

Drug-Drug Interactions with the Benzo Class

Lorazepam and oxazepam are metabolized by uridine diphosphate glucuronosyltransferases (UGTs). UGT inducers like carbamazepine, phenobarbital, phenytoin, and rifampin can induce metabolism and reduce efficacy of these benzo class members.[7] Concomitant use of CYP3A4 inhibitors, such as ketoconazole, can increase benzodiazepine concentrations, potentially leading to increased sedation and other adverse effects due to reduced metabolism.[37][38][39]

Contraindications for the Benzo Class

Warnings and Precautions

Contraindications for the benzo class include known angle-closure glaucoma, as their muscle relaxant effects can affect the sphincter pupillae muscle of the iris.[40] Benzodiazepines are also contraindicated in patients with prior hypersensitivity reactions, including anaphylaxis and angioedema.[[41]](#article-18220.r41] Remimazolam is contraindicated in patients with a history of hypersensitivity to dextran 40.[42]

Box Warning

The FDA includes a Box Warning for the benzo class regarding concomitant use with opioids, which can result in sedation, severe respiratory depression, coma, and death. This combination should be avoided.[43]

Monitoring Patients on the Benzo Class

As CNS depressants, the benzo class can inhibit respiratory drive. Therefore, careful monitoring of vital signs, especially blood pressure and respiratory rate, is essential after administration. Waveform capnography should be considered for respiratory status monitoring. While the therapeutic index of benzodiazepines is generally high, monitoring for respiratory depression is critical, as respiratory arrest has been reported with rapid IV injection.[44]

For alcohol withdrawal, monitor using the CIWA-Ar protocol and adjust benzo class dosage accordingly.[21] Patients receiving parenteral lorazepam or diazepam for alcohol withdrawal should be monitored for hyponatremia and metabolic acidosis due to propylene glycol in IV formulations.[12] In mechanically ventilated patients, monitor RASS to prevent oversedation, following SCCM guidelines for an individualized, patient-centered approach.[23][24][45]

Prescription drug monitoring programs can help healthcare professionals identify benzo class misuse.[46] Benzodiazepines are DEA-Scheduled IV drugs; flunitrazepam is a unique benzo class member with Schedule I penalties despite being Schedule IV.

Toxicity and Overdose of the Benzo Class

Signs and Symptoms of Benzo Class Overdose

Benzo class overdose can manifest as extreme sedation, cognitive impairment, and ataxia, often with slurred speech. Respiratory depression is a critical concern requiring immediate medical intervention. Cardiovascular effects, including hypotension and bradycardia, can also occur.

Management of Benzo Class Overdose

Management of benzo class overdose prioritizes airway, breathing, and circulation according to AHA guidelines.[47] Flumazenil, a GABA-A receptor antagonist, can reverse the sedative effects of benzodiazepines by competitive inhibition at the GABA-A receptor. However, flumazenil should be used cautiously as it can precipitate withdrawal seizures. Re-sedation can occur after flumazenil wears off.

Naloxone may be administered if opioid co-ingestion is suspected and the patient exhibits respiratory distress. Smaller naloxone doses (e.g., 0.05 mg) may be preferable to avoid opioid withdrawal and vomiting in sedated patients who may be unable to protect their airway.[48][49] Activated charcoal is generally contraindicated in benzo class overdose due to the risk of aspiration from altered mental status.[50]

Recommendations for Benzo Class Overdose

AHA 2023 guidelines provide recommendations for cardiac arrest or toxicity due to benzodiazepine poisoning. Isolated benzo class poisoning rarely causes life-threatening hemodynamic instability or respiratory depression. Flumazenil removes benzodiazepine-mediated sympathetic system suppression and can lead to cardiac events, especially with other arrhythmogenic drugs or hypoxia. Flumazenil may not fully reverse respiratory depression in mixed overdoses, and naloxone is often preferred when opioid co-ingestion is possible.[51]

Enhancing Healthcare Team Outcomes in Benzo Class Therapy

The benzo class is frequently prescribed in both outpatient and inpatient settings. While effective for sedation and anxiolysis, benzodiazepines carry potential risks. All healthcare professionals involved in prescribing and administering these agents must be fully aware of adverse effects, misuse, abuse potential, and the risk of physical dependence. Benzodiazepines are DEA-Scheduled IV drugs. Pharmacists play a crucial role in medication reconciliation and alerting clinicians to significant drug-drug interactions. Anesthesiologists and certified registered nurse anesthetists are vital in procedural sedation involving the benzo class.

Nurses are essential for monitoring patients, particularly in mechanically ventilated settings. Neurologists should be consulted for appropriate benzo class use, such as clobazam for Lennox-Gastaut syndrome. Intensivists are crucial when benzodiazepines are used for sedation in critical care. Emergency medicine physicians and nurses are vital for rapid stabilization in overdose situations. Psychiatrists are essential for patients with benzodiazepine use disorder. Liberal prescribing should be avoided due to high abuse potential, and regulatory bodies are increasingly scrutinizing benzo class prescriptions for appropriate justification and documentation.[52][[53]](#article-18220.r53]

Optimal benzo class therapy requires a collaborative interprofessional healthcare team including clinicians, specialists, pharmacists, and specialty-trained nurses. Interprofessional team-based models involving clinical pharmacists and primary care physicians can optimize therapy and minimize risks associated with benzo class use for anxiety and insomnia.[54]

Review Questions

(Review questions are not included as per instructions to only include title and content)

References

1.Maust DT, Solway E, Clark SJ, Kirch M, Singer DC, Malani P. Prescription and Nonprescription Sleep Product Use Among Older Adults in the United States. Am J Geriatr Psychiatry. 2019 Jan;27(1):32-41. [PubMed: 30409547]

2.Blanco C, Han B, Jones CM, Johnson K, Compton WM. Prevalence and Correlates of Benzodiazepine Use, Misuse, and Use Disorders Among Adults in the United States. J Clin Psychiatry. 2018 Oct 16;79(6) [PMC free article: PMC10309967] [PubMed: 30403446]

3.Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Front Psychiatry. 2020;11:595584. [PMC free article: PMC7786299] [PubMed: 33424664]

4.March KL, Twilla JD, Reaves AB, Self TH, Slayton MM, Bergeron JB, Sakaan SA. Lorazepam versus chlordiazepoxide for the treatment of alcohol withdrawal syndrome and prevention of delirium tremens in general medicine ward patients. Alcohol. 2019 Dec;81:56-60. [PubMed: 31176787]

5.Isojarvi J, Gidal BE, Chung S, Wechsler RT. Optimizing clobazam treatment in patients with Lennox-Gastaut syndrome. Epilepsy Behav. 2018 Jan;78:149-154. [PubMed: 29202277]

6.Brigo F, Igwe SC, Bragazzi NL, Lattanzi S. Clonazepam monotherapy for treating people with newly diagnosed epilepsy. Cochrane Database Syst Rev. 2019 Nov 19;2019(11) [PMC free article: PMC6863099] [PubMed: 31742671]

7.Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. [PubMed: 18384456]

8.Chiang LM, Wang HS, Shen HH, Deng ST, Tseng CH, Chen YI, Chou ML, Hung PC, Lin KL. Rectal diazepam solution is as good as rectal administration of intravenous diazepam in the first-aid cessation of seizures in children with intractable epilepsy. Pediatr Neonatol. 2011 Feb;52(1):30-3. [PubMed: 21385654]

9.Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017 Feb 15;13(2):307-349. [PMC free article: PMC5263087] [PubMed: 27998379]

10.Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, Bare M, Bleck T, Dodson WE, Garrity L, Jagoda A, Lowenstein D, Pellock J, Riviello J, Sloan E, Treiman DM. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016 Jan-Feb;16(1):48-61. [PMC free article: PMC4749120] [PubMed: 26900382]

11.Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B, Balas MC, van den Boogaard M, Bosma KJ, Brummel NE, Chanques G, Denehy L, Drouot X, Fraser GL, Harris JE, Joffe AM, Kho ME, Kress JP, Lanphere JA, McKinley S, Neufeld KJ, Pisani MA, Payen JF, Pun BT, Puntillo KA, Riker RR, Robinson BRH, Shehabi Y, Szumita PM, Winkelman C, Centofanti JE, Price C, Nikayin S, Misak CJ, Flood PD, Kiedrowski K, Alhazzani W. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018 Sep;46(9):e825-e873. [PubMed: 30113379]

12.The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. J Addict Med. 2020 May/Jun;14(3S Suppl 1):1-72. [PubMed: 32511109]

13.Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD., Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016 Jul 19;165(2):125-33. [PubMed: 27136449]

14.Kilpatrick GJ. Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent. Front Pharmacol. 2021;12:690875. [PMC free article: PMC8329483] [PubMed: 34354587]

15.Poisbeau P, Gazzo G, Calvel L. Anxiolytics targeting GABAA receptors: Insights on etifoxine. World J Biol Psychiatry. 2018;19(sup1):S36-S45. [PubMed: 30204559]

16.Sigel E, Steinmann ME. Structure, function, and modulation of GABA(A) receptors. J Biol Chem. 2012 Nov 23;287(48):40224-31. [PMC free article: PMC3504738] [PubMed: 23038269]

17.Griffin CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013 Summer;13(2):214-23. [PMC free article: PMC3684331] [PubMed: 23789008]

18.Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation. Curr Opin Anaesthesiol. 2020 Aug;33(4):506-511. [PubMed: 32530890]

19.Wilcock A, Charlesworth S, Twycross R, Waddington A, Worthington O, Murtagh FEM, Beavis J, King S, Mihalyo M, Kotlinska-Lemieszek A. Prescribing Non-Opioid Drugs in End-Stage Kidney Disease. J Pain Symptom Manage. 2017 Nov;54(5):776-787. [PubMed: 28843456]

20.Borrelli EP, Bratberg J, Hallowell BD, Greaney ML, Kogut SJ. Application of a diazepam milligram equivalency algorithm to assess benzodiazepine dose intensity in Rhode Island in 2018. J Manag Care Spec Pharm. 2022 Jan;28(1):58-68. [PMC free article: PMC10373022] [PubMed: 34949119]

21.Melkonian A, Patel R, Magh A, Ferm S, Hwang C. Assessment of a Hospital-Wide CIWA-Ar Protocol for Management of Alcohol Withdrawal Syndrome. Mayo Clin Proc Innov Qual Outcomes. 2019 Sep;3(3):344-349. [PMC free article: PMC6713876] [PubMed: 31485573]

22.Ghazavi M, Nasiri J, Yaghini O, Soltani R. Oral Diazepam in Febrile Seizures Following Acellular Pertussis Vaccination. Adv Biomed Res. 2019;8:29. [PMC free article: PMC6507365] [PubMed: 31114769]

23.Kress JP, Pohlman AS, O’Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000 May 18;342(20):1471-7. [PubMed: 10816184]

24.Hughes CG, Mailloux PT, Devlin JW, Swan JT, Sanders RD, Anzueto A, Jackson JC, Hoskins AS, Pun BT, Orun OM, Raman R, Stollings JL, Kiehl AL, Duprey MS, Bui LN, O’Neal HR, Snyder A, Gropper MA, Guntupalli KK, Stashenko GJ, Patel MB, Brummel NE, Girard TD, Dittus RS, Bernard GR, Ely EW, Pandharipande PP., MENDS2 Study Investigators. Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis. N Engl J Med. 2021 Apr 15;384(15):1424-1436. [PMC free article: PMC8162695] [PubMed: 33528922]

25.Gershkovich P, Wasan KM, Ribeyre C, Ibrahim F, McNeill JH. Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome. Drugs Context. 2015;4:212287. [PMC free article: PMC4544271] [PubMed: 26322116]

26.Wyne A, Rai R, Cuerden M, Clark WF, Suri RS. Opioid and benzodiazepine use in end-stage renal disease: a systematic review. Clin J Am Soc Nephrol. 2011 Feb;6(2):326-33. [PMC free article: PMC3052223] [PubMed: 21071517]

27.Creeley CE, Denton LK. Use of Prescribed Psychotropics during Pregnancy: A Systematic Review of Pregnancy, Neonatal, and Childhood Outcomes. Brain Sci. 2019 Sep 14;9(9) [PMC free article: PMC6770670] [PubMed: 31540060]

28.Antenatal and postnatal mental health: clinical management and service guidance. National Institute for Health and Care Excellence (NICE); London: Apr, 2018. [PubMed: 31990493]

29.Shyken JM, Babbar S, Babbar S, Forinash A. Benzodiazepines in Pregnancy. Clin Obstet Gynecol. 2019 Mar;62(1):156-167. [PubMed: 30628916]

30.Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Jan 15, 2024. Lorazepam. [PubMed: 30000290]

31.Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Oct 15, 2024. Midazolam. [PubMed: 30000294]

32.Uguz F. A New Safety Scoring System for the Use of Psychotropic Drugs During Lactation. 2021 Jan-Feb 01Am J Ther. 28(1):e118-e126. [PubMed: 30601177]

33.By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-2081. [PubMed: 37139824]

34.Crowe SF, Stranks EK. The Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis. Arch Clin Neuropsychol. 2018 Nov 01;33(7):901-911. [PubMed: 29244060]

35.LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jan 24, 2017. Benzodiazepines. [PMC free article: PMC547852] [PubMed: 31643621]

36.Lee A, Shirley M. Remimazolam: A Review in Procedural Sedation. Drugs. 2021 Jul;81(10):1193-1201. [PubMed: 34196946]

37.Weaver MF. Prescription Sedative Misuse and Abuse. Yale J Biol Med. 2015 Sep;88(3):247-56. [PMC free article: PMC4553644] [PubMed: 26339207]

38.Boulenc X, Nicolas O, Hermabessière S, Zobouyan I, Martin V, Donazzolo Y, Ollier C. CYP3A4-based drug-drug interaction: CYP3A4 substrates’ pharmacokinetic properties and ketoconazole dose regimen effect. Eur J Drug Metab Pharmacokinet. 2016 Feb;41(1):45-54. [PubMed: 25374256]

39.Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000 Jan;38(1):41-57. [PubMed: 10668858]

40.Park MY, Kim WJ, Lee E, Kim C, Son SJ, Yoon JS, Kim W, Namkoong K. Association between use of benzodiazepines and occurrence of acute angle-closure glaucoma in the elderly: A population-based study. J Psychosom Res. 2019 Jul;122:1-5. [PubMed: 31126405]

41.Haybarger E, Young AS, Giovannitti JA. Benzodiazepine Allergy With Anesthesia Administration: A Review of Current Literature. Anesth Prog. 2016 Fall;63(3):160-7. [PMC free article: PMC5011959] [PubMed: 27585420]

42.Shiratori T, Sato A, Fukuzawa M, Kondo N, Tanno S. Severe Dextran-Induced Anaphylactic Shock during Induction of Hypertension-Hypervolemia-Hemodilution Therapy following Subarachnoid Hemorrhage. Case Rep Crit Care. 2015;2015:967560. [PMC free article: PMC4480245] [PubMed: 26171255]

43.Aschenbrenner DS. Stronger Boxed Warning for Benzodiazepines. Am J Nurs. 2021 Mar 01;121(3):22-23. [PubMed: 33625005]

44.Hatlestad D. Capnography in sedation and pain management. Emerg Med Serv. 2005 Mar;34(3):65-9. [PubMed: 15839539]

45.Medlej K. Calculated decisions: Richmond Agitation-Sedation Scale (RASS). Emerg Med Pract. 2021 Mar 15;23(Suppl 3):CD3-CD4. [PubMed: 33729737]

46.Liang D, Guo H, Shi Y. Mandatory use of prescription drug monitoring program and benzodiazepine prescribing among U.S. Medicaid enrollees. Subst Abus. 2021;42(3):294-301. [PMC free article: PMC7202951] [PubMed: 31697195]

47.Panchal AR, Bartos JA, Cabañas JG, Donnino MW, Drennan IR, Hirsch KG, Kudenchuk PJ, Kurz MC, Lavonas EJ, Morley PT, O’Neil BJ, Peberdy MA, Rittenberger JC, Rodriguez AJ, Sawyer KN, Berg KM., Adult Basic and Advanced Life Support Writing Group. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020 Oct 20;142(16_suppl_2):S366-S468. [PubMed: 33081529]

48.Gallo AT, Hulse G. Pharmacological uses of flumazenil in benzodiazepine use disorders: a systematic review of limited data. J Psychopharmacol. 2021 Mar;35(3):211-220. [PubMed: 33426982]

49.Sivilotti ML. Flumazenil, naloxone and the ‘coma cocktail’. Br J Clin Pharmacol. 2016 Mar;81(3):428-36. [PMC free article: PMC4767210] [PubMed: 26469689]

50.Zellner T, Prasa D, Färber E, Hoffmann-Walbeck P, Genser D, Eyer F. The Use of Activated Charcoal to Treat Intoxications. Dtsch Arztebl Int. 2019 May 03;116(18):311-317. [PMC free article: PMC6620762] [PubMed: 31219028]

51.Lavonas EJ, Akpunonu PD, Arens AM, Babu KM, Cao D, Hoffman RS, Hoyte CO, Mazer-Amirshahi ME, Stolbach A, St-Onge M, Thompson TM, Wang GS, Hoover AV, Drennan IR., American Heart Association. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2023 Oct 17;148(16):e149-e184. [PubMed: 37721023]

52.Jørgensen MB, Osler M. Should benzodiazepines be avoided? Acta Psychiatr Scand. 2018 Aug;138(2):89-90. [PubMed: 30398297]

53.Revet A, Yrondi A, Montastruc F. [Good practices in prescribing benzodiazepines]. Presse Med. 2018 Oct;47(10):872-877. [PubMed: 30385184]

54.Furbish SML, Kroehl ME, Loeb DF, Lam HM, Lewis CL, Nelson J, Chow Z, Trinkley KE. A Pharmacist-Physician Collaboration to Optimize Benzodiazepine Use for Anxiety and Sleep Symptom Control in Primary Care. J Pharm Pract. 2017 Aug;30(4):425-433. [PMC free article: PMC5511764] [PubMed: 27480874]

Disclosure: Connor Bounds declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.